When Does The Cymbalta Patent Expire?

Please don't ask dumb questions!

 

The real question is when is the massive lawsuit being filed against lilly for marketing a highly addictive product then jacking the price up. Come now boys and girls...somebody had to know how severe the withdrawal is for some users. How many thousands of cymbalta users are going through enforced withdrawal due to inability to pay right this moment, I wonder. Its gonna rain and rain and rain...pity the company is already on such poor footing. Cant wait to see the ambulance chasers advertisements hit late night cable! " ?Have you or a loved one been prescribed the prescription drug known as Cymbalta?If so you may be eligible for substantial financial compensation! " Goodbye Lilly.

 

Suggestions to stop Cymbalta w/o side-effects:

option 1: taper from 60mg x 7days to 30mg x 7days to 20mg x 7days
option 2: ask your MD to switch you to fluoxetine 20mg daily for 1-2 weeks then d/c

R.Ph.

 

Generics will be on the shelves the moment the patent expires.

 

Only the original generic company to file vs the patent holder gets to market their generic version exclusively for the 1st six months after end of patent. Then any generic company may enter the market.

R.Ph.

 

And when Cymbalta goes generic, there will be no more Cymbalta samples. When there are no more Cymbalta samples to start patients on, doctors will start using samples of whatever similar product is in their sample closet.

 

Still plenty of symbyyax, serafem and oraflex samples lying about, looking for a home.

 

Any Prozac Weekly samples?

The only Oraflex samples around are the paperweights.

 

Just like generic Plavix and see how that worked out for the Cardio Special reps?

 

meaning what

 

Who is the original generic company? Will the generic be out in December?

 

The generic will be out in December. I do not know the original generic but several companies have already gotten FDA approval for generic duloxetine:

http://www.prweb.com/releases/2012/9/prweb9884167.htm

 

Chihuha Cymbalta soon to join Puppy Prozac.

 

How could this be? Who could see this coming?

 

Globally the generic has been produced for a decade now. Just not the US. We are special.

 

Where does all that "specialness" go come December?

 

Combine NERI with Prozac for a patent snri? Devilishly workable. Which means it will be done.

Freaking merry go round.

Why not a "special" amphetamine time-released formulation? Make it pink with "Lilly" on it. Mmm seem to recall something just like a few decades ago.

 

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm378282.htm
FDA NEWS RELEASE


For Immediate Release: Dec. 11, 2013
Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA approves first generic versions of antidepressant drug Cymbalta

The U.S. Food and Drug Administration today approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.

Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Sun Pharma Global FZE, Teva Pharmaceuticals USA, and Torrent Pharmaceuticals Ltd. have received FDA approval to market duloxetine in various strengths.

“Health care professionals and consumers can be assured that these FDA-approved generic drugs have met our rigorous standards,” said Kathleen Uhl, M.D., acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Generic drugs offer greater access to health care for many people.”

Depression is characterized by symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Episodes of depression often recur throughout a person's lifetime. Signs and symptoms of depression include: depressed mood, loss of interest in usual activities, significant change in weight or appetite, insomnia or excessive sleeping (hypersomnia), restlessness/pacing (psychomotor agitation), increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicide attempts or thoughts of suicide.

Duloxetine and other antidepressant drugs have a boxed warning describing the increased risk of suicidal thinking and behavior during initial treatment in children, adolescents, and young adults ages 18 to 24. The warning also says data do not show this increased risk in those older than 24 years and that patients ages 65 and older who take antidepressants have a decreased risk of suicidal thinking and behavior.

The warning says depression and other serious psychiatric disorders themselves are the most important causes of suicide and that close monitoring of patients starting these medications is necessary. Duloxetine must be dispensed with a patient medication guide that describes important information about the drug’s uses and risks.

Common adverse reactions reported by people taking Cymbalta include nausea, dry mouth, drowsiness, fatigue, decreased appetite, increased sweating, and dizziness.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Information about the availability of generic duloxetine can be obtained from the manufacturers.

For more information:
FDA: Understanding Generic Drugs
Information on specific drug products, Drugs@FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
# # #

Read our Blog: FDA Voice

Visit the FDA on Facebookdisclaimer icon, Flickrdisclaimer icon, YouTubedisclaimer icon and Twitterdisclaimer icon

RSS Feed for FDA News Releases